Last reviewed · How we verify
TETRAHYDROFOLATE
At a glance
| Generic name | TETRAHYDROFOLATE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma (PHASE3)
- Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer (PHASE1,PHASE2)
- Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery (EARLY_PHASE1)
- Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer (PHASE2)
- Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer (PHASE2)
- Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed (PHASE3)
- Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia (PHASE3)
- Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |